학술논문
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Document Type
Academic Journal
Author
Nooka AK; Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.; Weisel K; Department of Oncology, Hematology & Bone Marrow Transplantation, University Medical Center of Hamburg-Eppendorf, Hamburg, 20246, Germany.; van de Donk NW; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 1081 HV, The Netherlands.; Routledge D; Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC 3000, Australia.; Otero PR; Centro de Investigación Médica Aplicada, Clínica Universidad de Navarra-Pamplona, Navarra, 31008, Spain.; Song K; Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada.; Quach H; Department of Haematology, University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC 3065, Australia.; Callander N; Carbone Cancer Center, University of Wisconsin, Madison, WI WI 53705, USA.; Minnema MC; Department of Hematology, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands.; Trudel S; Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.; Jackson NA; GlaxoSmithKline, Stockley Park, UB11 1BT, UK.; Ahlers CM; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Im E; GlaxoSmithKline, Waltham, MA 02451, USA.; Cheng S; SpringWorks Therapeutics, Stamford, CT 06902, USA.; Smith L; SpringWorks Therapeutics, Stamford, CT 06902, USA.; Hareth N; Department of Medicine, Karolinska University Hospital, Stockholm, SE 171 76, Sweden.; Ferron-Brady G; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Brouch M; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Montes de Oca R; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Paul S; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Holkova B; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Gupta I; GlaxoSmithKline, Upper Providence, PA 19426, USA.; Kremer BE; GlaxoSmithKline, Waltham, MA 02451, USA.; Richardson P; Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Source
Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).